The findings showed that high expression levels of BUB1B, BUB3, or TTK were associated with better survival rates in serous ovarian cancer patients treated with paclitaxel compared to patients with low expression levels (Fig. S4). This evidence concerns the gene BUB1B and ovarian serous adenocarcinoma.